Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Indaptus Therapeutics files $200M mixed securities shelf  17:55
09/01/22
09/01
17:55
09/01/22
17:55
INDP

Indaptus Therapeutics

$2.47 /

-0.025 (-1.00%)

 
ShowHide Related Items >><<
INDP Indaptus Therapeutics
$2.47 /

-0.025 (-1.00%)

INDP Indaptus Therapeutics
$2.47 /

-0.025 (-1.00%)

01/31/22 H.C. Wainwright
Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
10/19/21
Fly Intel: Top five analyst upgrades
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
INDP Indaptus Therapeutics
$2.47 /

-0.025 (-1.00%)

Over a quarter ago
Earnings
Indaptus Therapeutics reports Q2 EPS (46c) vs (27c) last year » 08:05
08/08/22
08/08
08:05
08/08/22
08:05
INDP

Indaptus Therapeutics

$3.28 /

+0.17 (+5.47%)

As of June 30, 2022, the…

As of June 30, 2022, the Company had cash, cash equivalents and short-term investments of approximately $33.0 million. "We made substantial progress throughout the second quarter, highlighted by the FDA clearance of our IND application for systemically administered Decoy20. This important regulatory milestone keeps us on track to initiate our first in human clinical trial this year," said Jeffrey Meckler, Chief Executive Officer of Indaptus. "Despite advances in the immuno-oncology field, there still remains a great unmet need in the treatment of solid tumor cancers. We believe Decoy20 has the potential to effectively tackle these hard-to-treat tumors with its ability to activate both the innate and adaptive immune systems."

ShowHide Related Items >><<
INDP Indaptus Therapeutics
$3.28 /

+0.17 (+5.47%)

INDP Indaptus Therapeutics
$3.28 /

+0.17 (+5.47%)

01/31/22 H.C. Wainwright
Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
10/19/21
Fly Intel: Top five analyst upgrades
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
INDP Indaptus Therapeutics
$3.28 /

+0.17 (+5.47%)

Syndicate
Indaptus Therapeutics files $200M mixed securities shelf  16:33
06/01/22
06/01
16:33
06/01/22
16:33
INDP

Indaptus Therapeutics

$2.45 /

-0.05 (-2.00%)

 
ShowHide Related Items >><<
INDP Indaptus Therapeutics
$2.45 /

-0.05 (-2.00%)

INDP Indaptus Therapeutics
$2.45 /

-0.05 (-2.00%)

01/31/22 H.C. Wainwright
Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
10/19/21
Fly Intel: Top five analyst upgrades
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
INDP Indaptus Therapeutics
$2.45 /

-0.05 (-2.00%)

Hot Stocks
Indaptus Therapeutics jumps 33% to $3.33 after FDA clearance of IND application  07:50
05/19/22
05/19
07:50
05/19/22
07:50
INDP

Indaptus Therapeutics

$2.52 /

+0.04 (+1.61%)

 
ShowHide Related Items >><<
INDP Indaptus Therapeutics
$2.52 /

+0.04 (+1.61%)

INDP Indaptus Therapeutics
$2.52 /

+0.04 (+1.61%)

01/31/22 H.C. Wainwright
Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
10/19/21
Fly Intel: Top five analyst upgrades
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
INDP Indaptus Therapeutics
$2.52 /

+0.04 (+1.61%)

Hot Stocks
Indaptus announces FDA clearance of IND application to Decoy20 trial » 07:24
05/19/22
05/19
07:24
05/19/22
07:24
INDP

Indaptus Therapeutics

$2.52 /

+0.04 (+1.61%)

Indaptus Therapeutics…

Indaptus Therapeutics announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for a Phase 1 clinical trial in patients with advanced solid tumors where currently approved therapies have failed. The Company plans to initiate the clinical trial in the second half of 2022.

ShowHide Related Items >><<
INDP Indaptus Therapeutics
$2.52 /

+0.04 (+1.61%)

INDP Indaptus Therapeutics
$2.52 /

+0.04 (+1.61%)

01/31/22 H.C. Wainwright
Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
10/19/21
Fly Intel: Top five analyst upgrades
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
INDP Indaptus Therapeutics
$2.52 /

+0.04 (+1.61%)

Hot Stocks
Indaptus Therapeutics reports submission of IND for Decoy20 » 08:07
05/12/22
05/12
08:07
05/12/22
08:07
INDP

Indaptus Therapeutics

$2.32 /

-0.12 (-4.92%)

Indaptus announces the…

Indaptus announces the submission of its Investigational New Drug Application for Decoy20. The company continues to expect to initiate a Phase 1 clinical trial for Decoy20 targeting solid tumors in 2022. Importantly, the company has successfully completed GMP manufacturing and IND-enabling multi-dose toxicology studies that have not produced sustained induction of factors associated with cytokine release syndromes. Earlier pre-clinical data have demonstrated Decoy20's ability to eradicate established tumors in a murine model of hepatocellular carcinoma in combination with either a non-steroidal anti-inflammatory drug or an anti-PD-1 agent, and more efficiently with both. In combination with low-dose chemotherapy, Decoy candidates have also produced highly efficient eradication of established tumors in a mouse model of non-Hodgkin's lymphoma, also with induction of immunological memory.

ShowHide Related Items >><<
INDP Indaptus Therapeutics
$2.32 /

-0.12 (-4.92%)

INDP Indaptus Therapeutics
$2.32 /

-0.12 (-4.92%)

01/31/22 H.C. Wainwright
Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
10/19/21
Fly Intel: Top five analyst upgrades
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
INDP Indaptus Therapeutics
$2.32 /

-0.12 (-4.92%)

Earnings
Indaptus Therapeutics reports Q1 EPS (41c) vs. (31c) last year » 08:06
05/12/22
05/12
08:06
05/12/22
08:06
INDP

Indaptus Therapeutics

$2.32 /

-0.12 (-4.92%)

"We are delighted to…

"We are delighted to report the submission of our Investigational New Drug application for systemically administered Decoy20. The timing of this submission keeps us on track to initiate our first in human clinical trial this year and we look forward to working with the FDA as we move through the IND submission process," said Jeffrey Meckler, CEO of Indaptus. "Decoy20, with its ability to activate both the innate and adaptive immune systems as a multiple Toll-like receptor agonist, holds the promise to effectively combat solid tumor cancers, an area where even many of the new immuno-oncology approaches have failed."

ShowHide Related Items >><<
INDP Indaptus Therapeutics
$2.32 /

-0.12 (-4.92%)

INDP Indaptus Therapeutics
$2.32 /

-0.12 (-4.92%)

01/31/22 H.C. Wainwright
Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
10/19/21
Fly Intel: Top five analyst upgrades
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
INDP Indaptus Therapeutics
$2.32 /

-0.12 (-4.92%)

Earnings
Indaptus Therapeutics reports 2021 EPS ($1.89) vs ($1.84) last year » 07:03
03/21/22
03/21
07:03
03/21/22
07:03
INDP

Indaptus Therapeutics

$3.85 /

+0.205 (+5.62%)

As of December 31, 2021,…

As of December 31, 2021, the Company had cash and cash equivalents of approximately $39.1 million. "We enter 2022 excited about the future for Indaptus as we continue to advance our clinical readiness with site selection, toxicology studies and other tasks necessary for the successful clearance of our Investigational New Drug application," said Jeffrey Meckler, Chief Executive Officer of Indaptus. "With Dr. Litchev at the clinical helm, we look forward to his final evaluation of the study design and clinical strategy. We remain on track to initiate this important Phase 1 study of Decoy20 this year and look forward to bringing this novel, multi-targeted therapy to the fight against cancer."

ShowHide Related Items >><<
INDP Indaptus Therapeutics
$3.85 /

+0.205 (+5.62%)

INDP Indaptus Therapeutics
$3.85 /

+0.205 (+5.62%)

01/31/22 H.C. Wainwright
Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
10/19/21
Fly Intel: Top five analyst upgrades
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
INDP Indaptus Therapeutics
$3.85 /

+0.205 (+5.62%)

Conference/Events
Roth Capital to hold a conference » 04:55
03/16/22
03/16
04:55
03/16/22
04:55
ATNM

Actinium Pharmaceuticals

$4.66 /

+0.06 (+1.30%)

, AWKNF

Awakn Life Sciences

$1.32 /

+0.0183 (+1.41%)

, AXLA

Axcella Health

$1.94 /

-0.015 (-0.77%)

, CLNN

Clene

$2.44 /

-0.265 (-9.81%)

, COCP

Cocrystal Pharma

/

+

, FTRP

Field Trip Health

$1.02 /

-0.01 (-0.97%)

, FWBI

First Wave BioPharma

$1.07 /

+0.02 (+1.90%)

, FBIO

Fortress Biotech

$1.24 /

-0.01 (-0.80%)

, CMPS

Compass Pathways

$11.52 /

+0.31 (+2.77%)

, DARE

Dare Bioscience

$1.47 /

+0.02 (+1.38%)

, DCTH

Delcath Systems

$6.13 /

+0.01 (+0.16%)

, DHAC

Digital Health Acquisition

$9.97 /

+ (+0.00%)

, GLYC

GlycoMimetics

$1.03 /

+0.02 (+1.98%)

, KALV

KalVista

$14.49 /

+0.07 (+0.49%)

, KMPH

KemPharm

$5.11 /

+0.11 (+2.20%)

, LCI

Lannett

/

+

, LMAT

LeMaitre

$41.87 /

-0.08 (-0.19%)

, LGND

Ligand

$104.48 /

+4.18 (+4.17%)

, LUMO

Lumos Pharma

$8.86 /

-0.22 (-2.42%)

, MRKR

Marker Therapeutics

/

+

, PBLA

Panbela Therapeutics

$1.74 /

-0.04 (-2.25%)

, PIII

P3 Health Partners

$6.67 /

+0.18 (+2.77%)

, SKIN

Beauty Health

$15.60 /

-0.15 (-0.95%)

, SINT

Sintx Technologies

/

+

, MBRX

Moleculin Biotech

$1.28 /

+0.05 (+4.07%)

, MNPR

Monopar Therapeutics

$2.86 /

-0.07 (-2.39%)

, IRIX

Iridex

$4.09 /

-0.04 (-0.97%)

, IRMD

iRadimed

$46.67 /

+1.69 (+3.76%)

, INVO

INVO Bioscience

$2.20 /

-0.09 (-3.93%)

, INM

InMed Pharmaceuticals

/

+

, INDP

Indaptus Therapeutics

$3.17 /

-0.18 (-5.37%)

, ENSC

Ensysce Biosciences

$1.09 /

+0.035 (+3.32%)

, LIFE

aTyr Pharma

$4.74 /

+0.03 (+0.64%)

, ATAI

Atai Life Sciences

$4.94 /

-0.145 (-2.85%)

34th Annual ROTH…

34th Annual ROTH Conference to be held in Dana Point, CA on March 13-16. Webcast Link

ShowHide Related Items >><<
SKIN Beauty Health
$15.60 /

-0.15 (-0.95%)

SINT Sintx Technologies
/

+

PIII P3 Health Partners
$6.67 /

+0.18 (+2.77%)

PBLA Panbela Therapeutics
$1.74 /

-0.04 (-2.25%)

MRKR Marker Therapeutics
/

+

MNPR Monopar Therapeutics
$2.86 /

-0.07 (-2.39%)

MBRX Moleculin Biotech
$1.28 /

+0.05 (+4.07%)

LMAT LeMaitre
$41.87 /

-0.08 (-0.19%)

LIFE aTyr Pharma
$4.74 /

+0.03 (+0.64%)

LGND Ligand
$104.48 /

+4.18 (+4.17%)

LCI Lannett
/

+

KMPH KemPharm
$5.11 /

+0.11 (+2.20%)

KALV KalVista
$14.49 /

+0.07 (+0.49%)

IRMD iRadimed
$46.67 /

+1.69 (+3.76%)

INVO INVO Bioscience
$2.20 /

-0.09 (-3.93%)

INM InMed Pharmaceuticals
/

+

INDP Indaptus Therapeutics
$3.17 /

-0.18 (-5.37%)

GLYC GlycoMimetics
$1.03 /

+0.02 (+1.98%)

FWBI First Wave BioPharma
$1.07 /

+0.02 (+1.90%)

FTRP Field Trip Health
$1.02 /

-0.01 (-0.97%)

FBIO Fortress Biotech
$1.24 /

-0.01 (-0.80%)

ENSC Ensysce Biosciences
$1.09 /

+0.035 (+3.32%)

DCTH Delcath Systems
$6.13 /

+0.01 (+0.16%)

DARE Dare Bioscience
$1.47 /

+0.02 (+1.38%)

COCP Cocrystal Pharma
/

+

CMPS Compass Pathways
$11.52 /

+0.31 (+2.77%)

CLNN Clene
$2.44 /

-0.265 (-9.81%)

AXLA Axcella Health
$1.94 /

-0.015 (-0.77%)

ATNM Actinium Pharmaceuticals
$4.66 /

+0.06 (+1.30%)

ATAI Atai Life Sciences
$4.94 /

-0.145 (-2.85%)

ATNM Actinium Pharmaceuticals
$4.66 /

+0.06 (+1.30%)

09/15/21 Alliance Global Partners
Actinium price target lowered to $20 from $25 at Alliance Global Partners
08/03/21 H.C. Wainwright
Actinium Pharmaceuticals price target lowered to $45 from $57 at H.C. Wainwright
04/06/21 William Blair
Actinium's Q4 net loss roughly in line with projected loss, says William Blair
AWKNF Awakn Life Sciences
$1.32 /

+0.0183 (+1.41%)

02/01/22 H.C. Wainwright
Awakn Life Sciences initiated with a Buy at H.C. Wainwright
AXLA Axcella Health
$1.94 /

-0.015 (-0.77%)

10/12/21 Noble Capital
Axcella Health initiated with an Outperform at Noble Capital
09/22/21 Goldman Sachs
Axcella Health downgraded to Neutral from Buy at Goldman Sachs
07/30/21 JPMorgan
Axcella downgraded to Underweight on lack of catalysts at JPMorgan
07/30/21 JPMorgan
Axcella Health downgraded to Underweight from Neutral at JPMorgan
CLNN Clene
$2.44 /

-0.265 (-9.81%)

11/03/21 Cantor Fitzgerald
Clene price target lowered to $15 from $24 at Cantor Fitzgerald
11/02/21 Roth Capital
Roth reiterates Buy on Clene after unblinded analysis of CNM-Au8 in ALS trial
11/02/21 Benchmark
Benchmark would be buyer of Clene on weakness after RESCUE-ALS data
05/20/21 Maxim
Clene initiated with a Buy at Maxim
COCP Cocrystal Pharma
/

+

06/15/21 H.C. Wainwright
Cocrystal Pharma price target lowered to $4 from $4.50 at H.C. Wainwright
FTRP Field Trip Health
$1.02 /

-0.01 (-0.97%)

02/17/22 Stifel
Field Trip Health price target lowered to C$10.50 from C$11.50 at Stifel
11/22/21 H.C. Wainwright
Field Trip Health price target raised to $25 from $20 at H.C. Wainwright
11/18/21 Stifel
Field Trip Health price target raised to C$11.50 from C$10 at Stifel
09/01/21 H.C. Wainwright
Field Trip Health initiated with a Buy at H.C. Wainwright
FWBI First Wave BioPharma
$1.07 /

+0.02 (+1.90%)

12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
FBIO Fortress Biotech
$1.24 /

-0.01 (-0.80%)

10/26/21 Roth Capital
Avenue Therapeutics FDA panel positive for Fortress Biotech, says Roth Capital
09/29/21 H.C. Wainwright
H.C. Wainwright says Astra deal for Caelum to yield 'nice check' for Fortress
06/17/21 B. Riley
Fortress Biotech price target lowered to $8 from $9 at B. Riley
04/14/21 B. Riley
Fortress Biotech weakness yesterday a buying opportunity, says B. Riley
CMPS Compass Pathways
$11.52 /

+0.31 (+2.77%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
DARE Dare Bioscience
$1.47 /

+0.02 (+1.38%)

01/19/22 Brookline
Dare Bioscience assumed with a Buy at Brookline
07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
DCTH Delcath Systems
$6.13 /

+0.01 (+0.16%)

12/10/21 H.C. Wainwright
Delcath Systems initiated with a Buy at H.C. Wainwright
06/08/21 Roth Capital
Delcath Systems data suggest approvability, says Roth Capital
04/06/21 Roth Capital
Delcath Systems price target raised to $25 from $20 at Roth Capital
DHAC Digital Health Acquisition
$9.97 /

+ (+0.00%)

GLYC GlycoMimetics
$1.03 /

+0.02 (+1.98%)

11/12/21
Fly Intel: Top five analyst upgrades
11/12/21 Jefferies
GlycoMimetics upgraded to Buy at Jefferies as AML data looked 'very promising'
11/12/21 Jefferies
GlycoMimetics upgraded to Buy from Hold at Jefferies
09/27/21 Roth Capital
GlycoMimetics' Upro swiftly advancing in China, says Roth Capital
KALV KalVista
$14.49 /

+0.07 (+0.49%)

11/10/21 Roth Capital
KalVista FDA meeting feedback 'quite positive,' says Roth Capital
08/23/21 Roth Capital
KalVista could take 'substantial' share of HAE market, says Roth Capital
04/20/21 Roth Capital
KalVista selloff seems overdone after clinical hold, says Roth Capital
KMPH KemPharm
$5.11 /

+0.11 (+2.20%)

01/31/22 H.C. Wainwright
KemPharm upgraded to Buy from Neutral at H.C. Wainwright
05/26/21 Roth Capital
Orange Book lists 6 KemPharm SDX patents, confirms as an NCE, says Roth Capital
LCI Lannett
/

+

LMAT LeMaitre
$41.87 /

-0.08 (-0.19%)

02/25/22 Barrington
LeMaitre price target lowered to $54 from $62 at Barrington
09/16/21
Fly Intel: Top five analyst initiations
09/16/21 Jefferies
Jefferies starts LeMaitre at Buy on ArteGraft upside potential
09/16/21 Jefferies
LeMaitre initiated with a Buy at Jefferies
LGND Ligand
$104.48 /

+4.18 (+4.17%)

02/22/22 Benchmark
Ligand price target lowered to $130 from $180 at Benchmark
02/18/22 Barclays
Ligand price target lowered to $165 from $185 at Barclays
09/22/21 Barclays
Ligand price target raised to $180 from $174 at Barclays
08/25/21 H.C. Wainwright
Ligand gets royalty on sales of Merck's Vaxneuvance, says H.C. Wainwright
LUMO Lumos Pharma
$8.86 /

-0.22 (-2.42%)

08/05/21 Piper Sandler
Lumos shares trading below cash, says Piper Sandler
07/22/21 Roth Capital
Lumos Pharma price target lowered to $35 from $51 at Roth Capital
07/21/21 Piper Sandler
Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
07/21/21 H.C. Wainwright
Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
MRKR Marker Therapeutics
/

+

02/17/22 Roth Capital
Marker Therapeutics downgraded to Neutral from Buy at Roth Capital
02/17/22 Piper Sandler
Marker Therapeutics price target lowered to $4 from $5.50 at Piper Sandler
03/25/21 Piper Sandler
Marker Therapeutics initiated with an Overweight at Piper Sandler
03/19/21
Fly Intel: Top five analyst initiations
PBLA Panbela Therapeutics
$1.74 /

-0.04 (-2.25%)

02/23/22 Craig-Hallum
Panbela Therapeutics price target raised to $13 from $9 at Craig-Hallum
06/28/21 Roth Capital
Panbela Therapeutics initiated with a Buy at Roth Capital
PIII P3 Health Partners
$6.67 /

+0.18 (+2.77%)

01/04/22 William Blair
P3 Health Partners initiated with an Outperform at William Blair
12/28/21 Lake Street
Lake Street names 18 small cap best ideas for 2022
SKIN Beauty Health
$15.60 /

-0.15 (-0.95%)

03/14/22 Benchmark
Beauty Health price target raised to $23 from $18 at Benchmark
03/11/22 JPMorgan
Beauty Health initiated with an Overweight at JPMorgan
01/07/22 William Blair
William Blair starts Beauty Health with Outperform, sees 20%-plus growth
01/07/22 William Blair
Beauty Health initiated with an Outperform at William Blair
SINT Sintx Technologies
/

+

MBRX Moleculin Biotech
$1.28 /

+0.05 (+4.07%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
04/14/21 Roth Capital
Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
MNPR Monopar Therapeutics
$2.86 /

-0.07 (-2.39%)

11/01/21 H.C. Wainwright
Monopar Therapeutics initiated with a Buy at H.C. Wainwright
10/19/21 Roth Capital
Roth Capital bullish on Monopar Therapeutics after competitor trial fails
IRIX Iridex
$4.09 /

-0.04 (-0.97%)

03/02/22 Stifel
Iridex transferred with Buy rating at Stifel
IRMD iRadimed
$46.67 /

+1.69 (+3.76%)

11/02/21 Roth Capital
iRadimed price target raised to $42 from $36 at Roth Capital
INVO INVO Bioscience
$2.20 /

-0.09 (-3.93%)

01/19/22 Maxim
INVO Bioscience initiated with a Buy at Maxim
INM InMed Pharmaceuticals
/

+

11/29/21 H.C. Wainwright
InMed Pharmaceuticals initiated with a Buy at H.C. Wainwright
INDP Indaptus Therapeutics
$3.17 /

-0.18 (-5.37%)

01/31/22 H.C. Wainwright
Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
10/19/21
Fly Intel: Top five analyst upgrades
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
ENSC Ensysce Biosciences
$1.09 /

+0.035 (+3.32%)

11/30/21 Lake Street
Ensysce Biosciences initiated with a Buy at Lake Street
LIFE aTyr Pharma
$4.74 /

+0.03 (+0.64%)

11/11/21 Roth Capital
aTyr Pharma 2022 catalysts 'should be on your radar,' says Roth Capital
10/12/21 RBC Capital
aTyr Pharma initiated with an Outperform at RBC Capital
09/21/21 Piper Sandler
aTyr Pharma initiated with an Overweight at Piper Sandler
09/14/21 Oppenheimer
aTyr Pharma price target raised to $20 from $14 at Oppenheimer
ATAI Atai Life Sciences
$4.94 /

-0.145 (-2.85%)

11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/22/21 Canaccord
Atai Life Sciences weakness a buying opportunity, says Canaccord
SKIN Beauty Health
$15.60 /

-0.15 (-0.95%)

PIII P3 Health Partners
$6.67 /

+0.18 (+2.77%)

MRKR Marker Therapeutics
/

+

MNPR Monopar Therapeutics
$2.86 /

-0.07 (-2.39%)

MBRX Moleculin Biotech
$1.28 /

+0.05 (+4.07%)

LUMO Lumos Pharma
$8.86 /

-0.22 (-2.42%)

LMAT LeMaitre
$41.87 /

-0.08 (-0.19%)

LIFE aTyr Pharma
$4.74 /

+0.03 (+0.64%)

LGND Ligand
$104.48 /

+4.18 (+4.17%)

LCI Lannett
/

+

KALV KalVista
$14.49 /

+0.07 (+0.49%)

IRMD iRadimed
$46.67 /

+1.69 (+3.76%)

IRIX Iridex
$4.09 /

-0.04 (-0.97%)

INVO INVO Bioscience
$2.20 /

-0.09 (-3.93%)

INM InMed Pharmaceuticals
/

+

INDP Indaptus Therapeutics
$3.17 /

-0.18 (-5.37%)

GLYC GlycoMimetics
$1.03 /

+0.02 (+1.98%)

FTRP Field Trip Health
$1.02 /

-0.01 (-0.97%)

FBIO Fortress Biotech
$1.24 /

-0.01 (-0.80%)

DCTH Delcath Systems
$6.13 /

+0.01 (+0.16%)

DARE Dare Bioscience
$1.47 /

+0.02 (+1.38%)

COCP Cocrystal Pharma
/

+

CMPS Compass Pathways
$11.52 /

+0.31 (+2.77%)

CLNN Clene
$2.44 /

-0.265 (-9.81%)

AXLA Axcella Health
$1.94 /

-0.015 (-0.77%)

ATAI Atai Life Sciences
$4.94 /

-0.145 (-2.85%)

  • 16
    Sep
  • 14
    Jul
  • 18
    Jun
  • 30
    Apr
AXLA Axcella Health
$1.94 /

-0.015 (-0.77%)

SKIN Beauty Health
$15.60 /

-0.15 (-0.95%)

LIFE aTyr Pharma
$4.74 /

+0.03 (+0.64%)

IRMD iRadimed
$46.67 /

+1.69 (+3.76%)

IRIX Iridex
$4.09 /

-0.04 (-0.97%)

INM InMed Pharmaceuticals
/

+

FBIO Fortress Biotech
$1.24 /

-0.01 (-0.80%)

DHAC Digital Health Acquisition
$9.97 /

+ (+0.00%)

DCTH Delcath Systems
$6.13 /

+0.01 (+0.16%)

DARE Dare Bioscience
$1.47 /

+0.02 (+1.38%)

CMPS Compass Pathways
$11.52 /

+0.31 (+2.77%)

AXLA Axcella Health
$1.94 /

-0.015 (-0.77%)

AWKNF Awakn Life Sciences
$1.32 /

+0.0183 (+1.41%)

SKIN Beauty Health
$15.60 /

-0.15 (-0.95%)

LIFE aTyr Pharma
$4.74 /

+0.03 (+0.64%)

KMPH KemPharm
$5.11 /

+0.11 (+2.20%)

ENSC Ensysce Biosciences
$1.09 /

+0.035 (+3.32%)

CMPS Compass Pathways
$11.52 /

+0.31 (+2.77%)

ATAI Atai Life Sciences
$4.94 /

-0.145 (-2.85%)

Conference/Events
Roth Capital to hold a conference » 04:55
03/15/22
03/15
04:55
03/15/22
04:55
ATNM

Actinium Pharmaceuticals

$4.60 /

-0.2 (-4.17%)

, AWKNF

Awakn Life Sciences

$1.30 /

+0.0017 (+0.13%)

, AXLA

Axcella Health

$2.01 /

-0.035 (-1.71%)

, CLNN

Clene

$2.70 /

-0.11 (-3.91%)

, COCP

Cocrystal Pharma

/

+

, FTRP

Field Trip Health

$1.03 /

-0.02 (-1.90%)

, FWBI

First Wave BioPharma

$1.06 /

-0.07 (-6.19%)

, FBIO

Fortress Biotech

$1.24 /

-0.11 (-8.15%)

, CMPS

Compass Pathways

$11.17 /

-0.97 (-7.99%)

, DARE

Dare Bioscience

$1.45 /

-0.08 (-5.25%)

, DCTH

Delcath Systems

$6.12 /

+0.2 (+3.38%)

, DHAC

Digital Health Acquisition

$9.97 /

+0.01 (+0.10%)

, GLYC

GlycoMimetics

$1.01 /

-0.09 (-8.18%)

, KALV

KalVista

$14.39 /

-1.06 (-6.86%)

, KMPH

KemPharm

$5.00 /

-0.255 (-4.86%)

, LCI

Lannett

/

+

, LMAT

LeMaitre

$41.93 /

-0.56 (-1.32%)

, LGND

Ligand

$101.10 /

-3.44 (-3.29%)

, LUMO

Lumos Pharma

$8.86 /

-0.16 (-1.77%)

, MRKR

Marker Therapeutics

/

+

, PBLA

Panbela Therapeutics

$1.77 /

-0.04 (-2.21%)

, PIII

P3 Health Partners

$6.47 /

-0.385 (-5.62%)

, SKIN

Beauty Health

$15.75 /

-1.915 (-10.84%)

, SINT

Sintx Technologies

/

+

, MBRX

Moleculin Biotech

$1.23 /

-0.08 (-6.11%)

, MNPR

Monopar Therapeutics

$2.87 /

-0.07 (-2.38%)

, IRIX

Iridex

$4.10 /

+ (+0.00%)

, IRMD

iRadimed

$44.98 /

-1.645 (-3.53%)

, INVO

INVO Bioscience

$2.29 /

+0.02 (+0.88%)

, INM

InMed Pharmaceuticals

/

+

, INDP

Indaptus Therapeutics

$3.30 /

-0.305 (-8.46%)

, ENSC

Ensysce Biosciences

$1.06 /

-0.045 (-4.09%)

, LIFE

aTyr Pharma

$4.75 /

-0.5 (-9.52%)

, ATAI

Atai Life Sciences

$5.08 /

-0.145 (-2.78%)

34th Annual ROTH…

34th Annual ROTH Conference to be held in Dana Point, CA on March 13-16. Webcast Link

ShowHide Related Items >><<
SKIN Beauty Health
$15.75 /

-1.915 (-10.84%)

SINT Sintx Technologies
/

+

PIII P3 Health Partners
$6.47 /

-0.385 (-5.62%)

PBLA Panbela Therapeutics
$1.77 /

-0.04 (-2.21%)

MRKR Marker Therapeutics
/

+

MNPR Monopar Therapeutics
$2.87 /

-0.07 (-2.38%)

MBRX Moleculin Biotech
$1.23 /

-0.08 (-6.11%)

LMAT LeMaitre
$41.93 /

-0.56 (-1.32%)

LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

LGND Ligand
$101.10 /

-3.44 (-3.29%)

LCI Lannett
/

+

KMPH KemPharm
$5.00 /

-0.255 (-4.86%)

KALV KalVista
$14.39 /

-1.06 (-6.86%)

IRMD iRadimed
$44.98 /

-1.645 (-3.53%)

INVO INVO Bioscience
$2.29 /

+0.02 (+0.88%)

INM InMed Pharmaceuticals
/

+

INDP Indaptus Therapeutics
$3.30 /

-0.305 (-8.46%)

GLYC GlycoMimetics
$1.01 /

-0.09 (-8.18%)

FWBI First Wave BioPharma
$1.06 /

-0.07 (-6.19%)

FTRP Field Trip Health
$1.03 /

-0.02 (-1.90%)

FBIO Fortress Biotech
$1.24 /

-0.11 (-8.15%)

ENSC Ensysce Biosciences
$1.06 /

-0.045 (-4.09%)

DCTH Delcath Systems
$6.12 /

+0.2 (+3.38%)

DARE Dare Bioscience
$1.45 /

-0.08 (-5.25%)

COCP Cocrystal Pharma
/

+

CMPS Compass Pathways
$11.17 /

-0.97 (-7.99%)

CLNN Clene
$2.70 /

-0.11 (-3.91%)

AXLA Axcella Health
$2.01 /

-0.035 (-1.71%)

ATNM Actinium Pharmaceuticals
$4.60 /

-0.2 (-4.17%)

ATAI Atai Life Sciences
$5.08 /

-0.145 (-2.78%)

ATNM Actinium Pharmaceuticals
$4.60 /

-0.2 (-4.17%)

09/15/21 Alliance Global Partners
Actinium price target lowered to $20 from $25 at Alliance Global Partners
08/03/21 H.C. Wainwright
Actinium Pharmaceuticals price target lowered to $45 from $57 at H.C. Wainwright
04/06/21 William Blair
Actinium's Q4 net loss roughly in line with projected loss, says William Blair
AWKNF Awakn Life Sciences
$1.30 /

+0.0017 (+0.13%)

02/01/22 H.C. Wainwright
Awakn Life Sciences initiated with a Buy at H.C. Wainwright
AXLA Axcella Health
$2.01 /

-0.035 (-1.71%)

10/12/21 Noble Capital
Axcella Health initiated with an Outperform at Noble Capital
09/22/21 Goldman Sachs
Axcella Health downgraded to Neutral from Buy at Goldman Sachs
07/30/21 JPMorgan
Axcella downgraded to Underweight on lack of catalysts at JPMorgan
07/30/21 JPMorgan
Axcella Health downgraded to Underweight from Neutral at JPMorgan
CLNN Clene
$2.70 /

-0.11 (-3.91%)

11/03/21 Cantor Fitzgerald
Clene price target lowered to $15 from $24 at Cantor Fitzgerald
11/02/21 Roth Capital
Roth reiterates Buy on Clene after unblinded analysis of CNM-Au8 in ALS trial
11/02/21 Benchmark
Benchmark would be buyer of Clene on weakness after RESCUE-ALS data
05/20/21 Maxim
Clene initiated with a Buy at Maxim
COCP Cocrystal Pharma
/

+

06/15/21 H.C. Wainwright
Cocrystal Pharma price target lowered to $4 from $4.50 at H.C. Wainwright
FTRP Field Trip Health
$1.03 /

-0.02 (-1.90%)

02/17/22 Stifel
Field Trip Health price target lowered to C$10.50 from C$11.50 at Stifel
11/22/21 H.C. Wainwright
Field Trip Health price target raised to $25 from $20 at H.C. Wainwright
11/18/21 Stifel
Field Trip Health price target raised to C$11.50 from C$10 at Stifel
09/01/21 H.C. Wainwright
Field Trip Health initiated with a Buy at H.C. Wainwright
FWBI First Wave BioPharma
$1.06 /

-0.07 (-6.19%)

12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
FBIO Fortress Biotech
$1.24 /

-0.11 (-8.15%)

10/26/21 Roth Capital
Avenue Therapeutics FDA panel positive for Fortress Biotech, says Roth Capital
09/29/21 H.C. Wainwright
H.C. Wainwright says Astra deal for Caelum to yield 'nice check' for Fortress
06/17/21 B. Riley
Fortress Biotech price target lowered to $8 from $9 at B. Riley
04/14/21 B. Riley
Fortress Biotech weakness yesterday a buying opportunity, says B. Riley
CMPS Compass Pathways
$11.17 /

-0.97 (-7.99%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
DARE Dare Bioscience
$1.45 /

-0.08 (-5.25%)

01/19/22 Brookline
Dare Bioscience assumed with a Buy at Brookline
07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
DCTH Delcath Systems
$6.12 /

+0.2 (+3.38%)

12/10/21 H.C. Wainwright
Delcath Systems initiated with a Buy at H.C. Wainwright
06/08/21 Roth Capital
Delcath Systems data suggest approvability, says Roth Capital
04/06/21 Roth Capital
Delcath Systems price target raised to $25 from $20 at Roth Capital
DHAC Digital Health Acquisition
$9.97 /

+0.01 (+0.10%)

GLYC GlycoMimetics
$1.01 /

-0.09 (-8.18%)

11/12/21
Fly Intel: Top five analyst upgrades
11/12/21 Jefferies
GlycoMimetics upgraded to Buy at Jefferies as AML data looked 'very promising'
11/12/21 Jefferies
GlycoMimetics upgraded to Buy from Hold at Jefferies
09/27/21 Roth Capital
GlycoMimetics' Upro swiftly advancing in China, says Roth Capital
KALV KalVista
$14.39 /

-1.06 (-6.86%)

11/10/21 Roth Capital
KalVista FDA meeting feedback 'quite positive,' says Roth Capital
08/23/21 Roth Capital
KalVista could take 'substantial' share of HAE market, says Roth Capital
04/20/21 Roth Capital
KalVista selloff seems overdone after clinical hold, says Roth Capital
KMPH KemPharm
$5.00 /

-0.255 (-4.86%)

01/31/22 H.C. Wainwright
KemPharm upgraded to Buy from Neutral at H.C. Wainwright
05/26/21 Roth Capital
Orange Book lists 6 KemPharm SDX patents, confirms as an NCE, says Roth Capital
LCI Lannett
/

+

LMAT LeMaitre
$41.93 /

-0.56 (-1.32%)

02/25/22 Barrington
LeMaitre price target lowered to $54 from $62 at Barrington
09/16/21
Fly Intel: Top five analyst initiations
09/16/21 Jefferies
Jefferies starts LeMaitre at Buy on ArteGraft upside potential
09/16/21 Jefferies
LeMaitre initiated with a Buy at Jefferies
LGND Ligand
$101.10 /

-3.44 (-3.29%)

02/22/22 Benchmark
Ligand price target lowered to $130 from $180 at Benchmark
02/18/22 Barclays
Ligand price target lowered to $165 from $185 at Barclays
09/22/21 Barclays
Ligand price target raised to $180 from $174 at Barclays
08/25/21 H.C. Wainwright
Ligand gets royalty on sales of Merck's Vaxneuvance, says H.C. Wainwright
LUMO Lumos Pharma
$8.86 /

-0.16 (-1.77%)

08/05/21 Piper Sandler
Lumos shares trading below cash, says Piper Sandler
07/22/21 Roth Capital
Lumos Pharma price target lowered to $35 from $51 at Roth Capital
07/21/21 Piper Sandler
Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
07/21/21 H.C. Wainwright
Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
MRKR Marker Therapeutics
/

+

02/17/22 Roth Capital
Marker Therapeutics downgraded to Neutral from Buy at Roth Capital
02/17/22 Piper Sandler
Marker Therapeutics price target lowered to $4 from $5.50 at Piper Sandler
03/25/21 Piper Sandler
Marker Therapeutics initiated with an Overweight at Piper Sandler
03/19/21
Fly Intel: Top five analyst initiations
PBLA Panbela Therapeutics
$1.77 /

-0.04 (-2.21%)

02/23/22 Craig-Hallum
Panbela Therapeutics price target raised to $13 from $9 at Craig-Hallum
06/28/21 Roth Capital
Panbela Therapeutics initiated with a Buy at Roth Capital
PIII P3 Health Partners
$6.47 /

-0.385 (-5.62%)

01/04/22 William Blair
P3 Health Partners initiated with an Outperform at William Blair
12/28/21 Lake Street
Lake Street names 18 small cap best ideas for 2022
SKIN Beauty Health
$15.75 /

-1.915 (-10.84%)

03/14/22 Benchmark
Beauty Health price target raised to $23 from $18 at Benchmark
03/11/22 JPMorgan
Beauty Health initiated with an Overweight at JPMorgan
01/07/22 William Blair
William Blair starts Beauty Health with Outperform, sees 20%-plus growth
01/07/22 William Blair
Beauty Health initiated with an Outperform at William Blair
SINT Sintx Technologies
/

+

MBRX Moleculin Biotech
$1.23 /

-0.08 (-6.11%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
04/14/21 Roth Capital
Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
MNPR Monopar Therapeutics
$2.87 /

-0.07 (-2.38%)

11/01/21 H.C. Wainwright
Monopar Therapeutics initiated with a Buy at H.C. Wainwright
10/19/21 Roth Capital
Roth Capital bullish on Monopar Therapeutics after competitor trial fails
IRIX Iridex
$4.10 /

+ (+0.00%)

03/02/22 Stifel
Iridex transferred with Buy rating at Stifel
IRMD iRadimed
$44.98 /

-1.645 (-3.53%)

11/02/21 Roth Capital
iRadimed price target raised to $42 from $36 at Roth Capital
INVO INVO Bioscience
$2.29 /

+0.02 (+0.88%)

01/19/22 Maxim
INVO Bioscience initiated with a Buy at Maxim
INM InMed Pharmaceuticals
/

+

11/29/21 H.C. Wainwright
InMed Pharmaceuticals initiated with a Buy at H.C. Wainwright
INDP Indaptus Therapeutics
$3.30 /

-0.305 (-8.46%)

01/31/22 H.C. Wainwright
Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
10/19/21
Fly Intel: Top five analyst upgrades
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
ENSC Ensysce Biosciences
$1.06 /

-0.045 (-4.09%)

11/30/21 Lake Street
Ensysce Biosciences initiated with a Buy at Lake Street
LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

11/11/21 Roth Capital
aTyr Pharma 2022 catalysts 'should be on your radar,' says Roth Capital
10/12/21 RBC Capital
aTyr Pharma initiated with an Outperform at RBC Capital
09/21/21 Piper Sandler
aTyr Pharma initiated with an Overweight at Piper Sandler
09/14/21 Oppenheimer
aTyr Pharma price target raised to $20 from $14 at Oppenheimer
ATAI Atai Life Sciences
$5.08 /

-0.145 (-2.78%)

11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/22/21 Canaccord
Atai Life Sciences weakness a buying opportunity, says Canaccord
SKIN Beauty Health
$15.75 /

-1.915 (-10.84%)

PIII P3 Health Partners
$6.47 /

-0.385 (-5.62%)

MRKR Marker Therapeutics
/

+

MNPR Monopar Therapeutics
$2.87 /

-0.07 (-2.38%)

MBRX Moleculin Biotech
$1.23 /

-0.08 (-6.11%)

LUMO Lumos Pharma
$8.86 /

-0.16 (-1.77%)

LMAT LeMaitre
$41.93 /

-0.56 (-1.32%)

LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

LGND Ligand
$101.10 /

-3.44 (-3.29%)

LCI Lannett
/

+

KALV KalVista
$14.39 /

-1.06 (-6.86%)

IRMD iRadimed
$44.98 /

-1.645 (-3.53%)

IRIX Iridex
$4.10 /

+ (+0.00%)

INVO INVO Bioscience
$2.29 /

+0.02 (+0.88%)

INM InMed Pharmaceuticals
/

+

INDP Indaptus Therapeutics
$3.30 /

-0.305 (-8.46%)

GLYC GlycoMimetics
$1.01 /

-0.09 (-8.18%)

FTRP Field Trip Health
$1.03 /

-0.02 (-1.90%)

FBIO Fortress Biotech
$1.24 /

-0.11 (-8.15%)

DCTH Delcath Systems
$6.12 /

+0.2 (+3.38%)

DARE Dare Bioscience
$1.45 /

-0.08 (-5.25%)

COCP Cocrystal Pharma
/

+

CMPS Compass Pathways
$11.17 /

-0.97 (-7.99%)

CLNN Clene
$2.70 /

-0.11 (-3.91%)

AXLA Axcella Health
$2.01 /

-0.035 (-1.71%)

ATAI Atai Life Sciences
$5.08 /

-0.145 (-2.78%)

  • 16
    Sep
  • 14
    Jul
  • 18
    Jun
  • 30
    Apr
AXLA Axcella Health
$2.01 /

-0.035 (-1.71%)

SKIN Beauty Health
$15.75 /

-1.915 (-10.84%)

LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

IRMD iRadimed
$44.98 /

-1.645 (-3.53%)

IRIX Iridex
$4.10 /

+ (+0.00%)

INM InMed Pharmaceuticals
/

+

FBIO Fortress Biotech
$1.24 /

-0.11 (-8.15%)

DHAC Digital Health Acquisition
$9.97 /

+0.01 (+0.10%)

DCTH Delcath Systems
$6.12 /

+0.2 (+3.38%)

DARE Dare Bioscience
$1.45 /

-0.08 (-5.25%)

CMPS Compass Pathways
$11.17 /

-0.97 (-7.99%)

AXLA Axcella Health
$2.01 /

-0.035 (-1.71%)

AWKNF Awakn Life Sciences
$1.30 /

+0.0017 (+0.13%)

SKIN Beauty Health
$15.75 /

-1.915 (-10.84%)

LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

KMPH KemPharm
$5.00 /

-0.255 (-4.86%)

ENSC Ensysce Biosciences
$1.06 /

-0.045 (-4.09%)

CMPS Compass Pathways
$11.17 /

-0.97 (-7.99%)

ATAI Atai Life Sciences
$5.08 /

-0.145 (-2.78%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.